Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Capital Expenditures (2018 - 2025)

X4 Pharmaceuticals' Capital Expenditures history spans 8 years, with the latest figure at $500000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 115.75% year-over-year to $500000.0; the TTM value through Dec 2025 reached $500000.0, up 53.37%, while the annual FY2025 figure was $500000.0, 53.37% up from the prior year.
  • Capital Expenditures reached $500000.0 in Q4 2025 per XFOR's latest filing, up from -$3.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.3 million in Q3 2024 to a low of -$3.2 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $94352.9, with a median of $34000.0 recorded in 2022.
  • The largest YoY upside for Capital Expenditures was 13128.0% in 2024 against a maximum downside of 9168.57% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $13000.0 in 2021, then surged by 161.54% to $34000.0 in 2022, then grew by 2.94% to $35000.0 in 2023, then plummeted by 9168.57% to -$3.2 million in 2024, then surged by 115.75% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Capital Expenditures are $500000.0 (Q4 2025), -$3.2 million (Q4 2024), and $3.3 million (Q3 2024).